May. 27 at 10:10 AM
$MNOV Today's IR confirmed that Last Patient Last Visit (LPLV) is complete for
$MNOV's NAFLD trial targeting Type 2 Diabetes (T2DM) patients.
Keep in mind, a previous small P2 already crushed the triglyceride (TG) reduction endpoint (p<0.0001). This time, they’ve enriched the trial by specifically targeting T2DM patients, the exact subgroup that showed the most massive TG drops in the past data.
With the TG reduction essentially a given, the real key to watch is the co-primary endpoint: how much it reduces liver fat (CAP score). Furthermore, if we see any exploratory trends indicating fibrosis improvement, this could be absolutely massive.
